Stéphanie BLANCHIN
Deputy CEO
Stéphanie BLANCHIN boasts a long experience in development and characterization of monoclonal antibodies for diagnostics (CHU de Caen) as well as therapeutic purposes (PX'Therapeutics). After her PhD in Immunology at Aix-Marseille Université (AMU), she pursued a postdoctoral internship in the Department of Medical Biochemistry at Cardiff University before joining the laboratory of Immunology and immunopathology of the CHU of Caen. Building on her experience and before joining MI-mAbs, she started and directed a platform dedicated to the generation of therapeutic monoclonal antibodies within the biotechnology company PX’Therapeutics. In 2013, she joined the MI-mAbs platform within Protisvalor SAS as Head of the Antibodies group and Deputy Scientific Director. She is currently Deputy CEO, at MImAbs SAS.
Jacques FIESCHI
Scientific Director
Jacques FIESCHI, PhD in immunology (University of Aix-Marseille/CNRS) and former postdoctoral fellow at the French Atomic Energy Commission, worked at Beckman Coulter on the specificity of anti-steroid antibodies and the development of diagnostic tests. After joining QIAGEN-Marseille as head of project management, he helped found HalioDx, a pioneer in immuno-oncology diagnostics, where he headed R&D and initiated contract research activities for the pharmaceutical and biotech industries. His teams' innovations include Brightplex® technology (multiplex IHC), the application of AI to the discovery of biomarkers on histological section images, and the development of original high-throughput DNA/RNA sequencing methods. These tools are used to monitor clinical trials. Jacques is currently Scientific Director at MImAbs SAS.
Marie HOMMEL
Business Development Director
Marie HOMMEL obtained a PhD in molecular biology from the Institut National Polytechnique de Toulouse. With 16 years of experience in client partnership roles, including Business Development in human health and Sales Management for France at Promega Corporation, she has particularly focused on innovative technologies for both fundamental and applied research. She has established numerous partnerships with pharmaceutical laboratories, biotech companies, and academic institutions. After dedicating 7 years to managing sales teams and customer service, she decided to apply her experience and industry knowledge to support MImAbs. She joined the team in June 2024 with the goal of structuring and strengthening client partnerships and expanding collaborations primarily in Europe and globally.
Laurent POUYET
Head of Operations
Laurent POUYET has a long experience using in vitro and in vivo models for the validation of drug candidates in cancer and inflammation. He holds a PhD in Immunology from Aix-Marseille Université (AMU) during which he worked at the Immunology Center of Marseille-Luminy (CIML). Laurent POUYET was then a postdoctoral fellow first at the University of California San Francisco (UCSF), thenat the Marseille Cancer Research Center (CRCM) where he developed several models to reproduce the biological mechanisms involved in cancer and inflammatory diseases. Building on his experience, he worked at TrGET, the pre-clinical assay platform of the Paoli-Calmettes Institute (IPC) before joining MImAbs.
Patrick VLIEGHE
Head of Administration and Finance
Patrick VLIEGHE holds a Ph.D. degree in Medicinal Chemistry and a Specialized Master’s degree in Healthcare Company Management at Euromed Management (now KEDGE Business School). He has over 20 years of experience in pharma/biotech, technology transfer and financing of innovation, working notably on various projects at the interface of science and business development. Among several experiences, he was Head of Development at Vect-Horus (a drug targeting company), Technology Transfer Manager at SATT Sud-Est (a Technology Transfer Office), and Head of Finance & Administrative Operations on MI-mAbs Platform at Protisvalor. He is now Senior Manager, Administration & Finance, at MImAbs SAS.